Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
Day One Biopharmaceuticals, Inc. (DAWN) had Return on Equity of -4.82% for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
$53.72M |
|
$-21.28M |
|
$6.08M |
|
$47.64M |
|
$81.18M |
|
$-27.46M |
|
$4.20M |
|
$-23.25M |
|
$-23.25M |
|
$-21.28M |
|
$-21.28M |
|
$-21.28M |
|
$-21.28M |
|
$-27.46M |
|
$-26.46M |
|
103.21M |
|
103.21M |
|
$-0.21 |
|
$-0.21 |
|
| Balance Sheet Financials | |
$485.10M |
|
$2.14M |
|
$22.73M |
|
$507.83M |
|
$60.52M |
|
-- |
|
$6.14M |
|
$66.67M |
|
$441.16M |
|
$423.14M |
|
$441.16M |
|
102.98M |
|
| Cash Flow Statement Financials | |
$-103.76M |
|
$174.65M |
|
$1.22M |
|
$124.97M |
|
$197.08M |
|
$72.11M |
|
$44.39M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.02 |
|
-- |
|
-- |
|
-- |
|
-- |
|
88.68% |
|
-51.12% |
|
-51.12% |
|
-- |
|
-43.29% |
|
-39.61% |
|
$-104.05M |
|
-- |
|
-- |
|
-- |
|
0.11 |
|
0.96 |
|
2.01 |
|
44.79 |
|
|
Return on Equity |
-4.82% |
-5.03% |
|
-4.19% |
|
-4.82% |
|
$4.28 |
|
$-1.01 |
|
$-1.01 |
|